ABSTRACT: To address the need for highly potent, metabolically stable, and selective agonists, antagonists, and inverse agonists at the melanocortin receptor subtypes, conformationally constrained indolo-and benzazepinone residues were inserted into the α-MSH pharmacophore, His 6 -Phe
T he endogenous melanocortin peptides include the α-, β-, and γ-melanocyte stimulating hormones (MSHs). These peptide hormones derive from posttranslational processing of the pro-opiomelanocortin (POMC) prehormone. 1−4 They play a role in a wide range of biological and physiological responses such as feeding and learning behavior, sexual function, and energy homeostasis. The melanocortin peptides operate through interactions with the G protein-coupled melanocortin receptors in both the peripheral and central nervous system and activate the adenylate cyclase second messenger signal transduction cascade. 1−4 To date five melanocortin receptor subtypes have been identified. 1−4 It has been observed that the primary native ligand for MC1R, MC3R, MC4R, and MC5R is α-melanocyte stimulating hormone (α-MSH, Ac-Ser-Tyr-Ser-Met-Glu-HisPhe-Arg-Trp-Gly-Lys-Pro-Val-NH 2 ). The native ligands possess neither a high selectivity for any of the above-mentioned MC receptors 5 nor a long half-life time as they are rapidly hydrolyzed by proteases. In order to establish the biological functions of the individual MC receptors, the need for highly potent, metabolically stable, and selective agonists, antagonists, and inverse agonists for the four receptors MC1R, MC3R, MC4R, and MC5R became apparent. 5 Since all melanocortin peptides possess a central and conserved "His-Phe-Arg-Trp" pharmacophore tetrapeptide sequence, most studies have focused on modifications at the level of this "message" domain. 6, 7 Initially, α-MSH was modified through the replacement of Met 4 by the pseudoisosteric amino acid norleucine (Nle) to prevent oxidation of its side chain, and the configuration of ]-α-MSH (MT-I) revealed not only to be more potent than α-MSH but also to have a higher in vivo stability and improved pharmacokinetics. 8 In addition, molecular modeling and NMR studies showed that the bioactive conformation of several cyclic ligands involved a β-turn structure at the level of the tetrapeptide pharmacophore. One of these potent cyclic analogues was a lactam (Ac-Nlec[Asp-His-D-Phe-Arg-Trp-Lys]-NH 2 , MT-II), which proved to be an extremely potent, but nonselective, agonist of human MC1R, MC3R, MC4R, and MC5R. 9, 10 In order to design potent and more selective peptide melanocortin ligands, several interesting structural modifications of MT-II were reported. 11 The replacement of His 6 by Pro in MT-II by Grieco et Upon substitution of His 6 in SHU-9119 by conformationally restricted amino acids, selective antagonists for the hMC3R and hMC4R were discovered. 14, 15 Hence, the importance of position 6 with regard to activity and MCR selectivity was demonstrated. 14, 15 Previously, we replaced the His 6 -D-Phe 7 dipeptide segment in MT-II by an Aba-Xxx motif (with Aba = 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one, Figure 1) . 16 Such azepinones are frequently used in our group and by others for the improvement of peptide stability, selectivity, and potency.
16−21
Aba can be viewed as a topographically constrained Phe building block. Molecular modeling indicated a good backbone overlap of all Aba-containing analogues with the proposed conformation of MT-II. 16 On the basis of the analysis of C α (i)−C α (i + 3) distances and the distances between the CO group of Asp 5 and the NH group of Arg 8 , the β-turn conformation was, however, not adopted by these analogues. The local constraint in the Aba-containing linear analogue of MT-II (Aba-1, Figure 1 ) was not sufficient to induce efficient binding affinity. Gratifyingly, the cyclic lactam analogue Aba-2 with the "Aba " motif proved to be a selective hMC3R antagonist (IC 50 of 50 nM at hMC3R). We concluded that the Aba building block needed to be used in conjunction with a global conformational constraint from these results since the linear analogue Aba-1 did not bind at concentrations up to 10 μM. 16 Haskell-Luevano and co-workers prepared a large series of analogues of the linear tetrapeptide Ac-His-D-Phe-Arg-Trp-NH 2 in which the Phe 7 residue was modified via the replacement of other aromatic residues and various substituents at the paraposition of the benzyl side chain of D-Phe 7 . They obtained an improved selectivity for the mouse (m)MC3R versus the mMC4R as well as a differentiation of agonist versus antagonist activity. 22, 23 This information could pave the way to the development of low molecular weight peptidomimetics as the tetrapeptide ligands are of intermediate molecular weight.
22−24 Proneth and co-workers modified the melanocortin tetrapeptide at the paraposition of the D-Phe 7 side chain. Halogenation at this position was used to unravel important side chain determinants for differentiation of the agonist versus antagonist activity of the mMC3R. 23 By insertion of a pF-D-Phe or pCl-D-Phe residue, they achieved good to moderate activation of mMC1R and mMC3R and excellent activation of mMC4R and mMC5R. 23 The study presented herein employs ligand−receptor structure−activity relationship (SAR) studies of locally constrained pharmacophore tetrapeptides 1−5 ( Figure 2 ) to investigate the requirements for receptor selectivity and for differentiation of agonist versus antagonist activity at the human melanocortin receptors MC1R, MC3R, MC4R, and MC5R. Since the MC2R is only activated by ACTH, it has been excluded from this study. Aiming at compact and constrained tetrapeptide analogues, we decided to replace the His 6 residue in the tetrapeptide pharmacophore with Aia, Aba, and Ata scaffolds ( Figure 2 ) and to evaluate their influence on receptor selectivity and agonist versus antagonist activity ( Table 1) .
The affinity for tetrapeptide ligands 1−5 was evaluated by competition binding experiments that were carried out using HEK293 cells, which stably expressed the human MC1, MC3, MC4, and MC5 receptors. 15 The activity at these receptors was evaluated in the same cells using a cAMP assay. 15 The binding affinities, expressed as IC 50 values, and the cAMP accumulation data are compared to MT-II and presented in Table 1 . Introduction of the Aia-D-Phe dipeptidomimetic in the linear pharmacophoric sequence (tetrapeptide 1) resulted in weak micromolar antagonist affinity for the hMC1R, nanomolar partial agonism at hMC3R (EC 50 = 52 nM), excellent partial agonism at hMC4R (EC 50 = 0.3 nM), and moderate antagonism at the hMC5R. The fact that 1 was unable to displace the radioligand at the hMC3R (and with low potency at the hMC4R) is an indication of allosteric binding at these receptors. Fluorination of the para-position of D-Phe 7 led to enhanced activity at the hMCRs, 23 as low nanomolar selective agonist activity (IC 50 = 6.5 nM; EC 50 = 13 nM) was indeed observed at hMC4R for tetrapeptide 2. In addition, this substitution gave moderate nanomolar binding as well as weak partial agonism at hMC1R and hMC5R. In contrast to the pF-D-Phe 7 tetrapeptide 2, which resulted in a selective hMC4R agonist, the pBr-D-Phe 7 tetrapeptide 3 showed significant loss in binding affinity to hMC4R (IC 50 = 200 nM), but resulted in a potent allosteric partial agonist (EC 50 = 0.3 nM and 80 activity %) at this receptor. In addition, tetrapeptide 3 is a weak agonist at hMC1R, a partial agonist at hMC3R, and a moderate antagonist at hMC5R (IC 50 = 70 nM). These affinities reflect the importance of the presence and nature (i.e., van der Waals radius) of the halogen substituent, next to that of the conformationally constrained Aia residue. Whereas the full agonist activity observed in Aia tetrapeptide 2 against hMC4R renders it a good candidate for further modifications, tetrapeptide 1 might also serve as a good template for the development of an allosteric hMC4R partial agonist. The aminobenzazepinone Aba-D-Phe analogue 4 displayed very weak agonist activity on hMC4R (IC 50 = 220 nM). In contrast, it resulted in a selective antagonist for hMC5R (IC 50 = 37 nM), which renders it an ideal template for the investigation of hMC5R antagonism. In contrast to the Aia and Aba analogues, the Ata-D-Phe analogue 5 showed no specific subtype receptor selectivity. We did not, therefore, focus on this analogue in subsequent docking studies (see below).
The preferential conformations of the most promising peptidic ligands 2 and 4 were analyzed by 2D ROESY NMR spectroscopy in DMSO solution at room temperature. The resulting distance constraints and homonuclear 3 J HN,HA couplings (typically 7−9 Hz) were employed for restraining main chain conformations in both cases. Unfortunately, conformational analysis by NMR was unable to determine a preferred topology for tetrapeptides 2 and 4 since the topologies of the ten lowest energy conformers were all substantially different. We concluded, therefore, that preorganization in solution was absent or very limited. In contrast to earlier studies, 25 this result could be explained by the fact that the conformational constraint was each time introduced as the first amino acid of the tetrapeptide sequence (Figure 2) . Peptides 2 and 4 were docked into the active state model of hMC4R proposed by Mosberg et al., 26 which was also used in the docking study of MT-II and SHU-9119 by Grieco and coworkers. 27 Upon docking of the peptide ligands, multiple binding poses were generated and clustered, yielding two clusters for peptide 2 and one larger cluster for analogue 4. The binding modes selected are high-ranking poses, which occurred multiple times among the best scoring models. The binding mode for both peptides positioned the conformationally restricted Aia or Aba residues in a hydrophobic pocket at the bottom of the extracellular binding site as shown in Figures 3  and 4b , also shown in Figures 3 and 4a . 26 The residues of [Nle In order to understand the selective hMC5R antagonist activity of peptidomimetic 4, we compared the binding of peptides 4 and 2 to hMC5R as shown in Figure 5 . The best docking pose of Aba-containing peptide 4 in hMC5R is very similar to the one in hMC4R: the Aba and D-Phe residues position themselves at the bottom of the hydrophobic part of the binding pocket and interact with conserved residues, such as Phe 254 . The Aia peptide 2, however, either fails to dock into the binding site or assumes a docking pose in which the Aia residue is located outside the binding pocket, while Trp and DPhe residues occupy the hydrophobic interior. This suggests that binding of peptide 2 to hMC5R is sterically hindered by the bulkiness of the Aia residue, while the Aba residue in peptide 4 fits into the binding pocket but is unable to activate the receptor.
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In conclusion, the insertion of constrained aminobenzo-and indoloazepinone-based residues into the core melanocortin tetrapeptides has resulted in compact and selective human melanocortin receptor ligands. The nature (steric bulk) and substitution pattern (para-halogenation) are important structural features for the modulation of receptor affinity, selectivity, and activity in these constrained peptides. Peptide 2 is a very potent and selective agonist for hMC4R, rendering it a good candidate for studies related to obesity and diabetes. Moreover, the newly discovered antagonist activity of peptide 4 at hMC5R can prove very useful to studies investigating anxiety and other neurological disorders. As further modification of the azepinone cores can improve and fine-tune the pharmacodynamics of these ligands, they represent valuable tools toward the unravelling of the individual role of each receptor subtype, but they may also be used for the development of specific 
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